Amaila Ramzan, Ali Mansoor, Hamid Majeed


Hepatic biopsy is as an invasive procedure which has inherent risk of complications requiring caution in patientselection as well as technical aspects of biopsy. The purpose of this audit was to evaluate the incidence of complications associated with parenchymal liver biopsy and to compare with the standards set by Royal College of Radiologists advisory committee. This audit was performed in Radiology department of Jinnah Hospital Lahore. Thirty consecutive patients in whom parenchymal liver biopsy was being performed for chronic hepatitis were audited for the incidence of complications, followed by re-audit to look for improvement in local practice. In the 1st audit, 13 out of 30 patients (43%) complained of pain. Eleven out of 30 (36.6%) complained of minor pain that did not require medication against the target of < 30% and 3 out of 30 (10%) required analgesia against the target of <3%. Rests of the standards were met. The re-audit performed after implementation of changes following therecommendations made after 1rst audit showed good compliance with standards. The Operator expertise, emphasis on consenting/ proper counseling and use of premedication were found to improve outcome that resulted in meeting the standards.

Full Text:



Vijayaraghavan GR, David S, Bermudez-Allende M, Sarwat H. Imaging-guided Parenchymal Liver Biopsy: How We Do It. J Clin Imaging Sci. 2010;1:30.

Howlett DC, Drinkwater KJ, Lawrence D, Barter S, Nicholson T. Findings of the UK national audit evaluating image-guided or image-assisted liver biopsy. I. Procedural aspects, diagnostic adequacy, and accuracy. Radiology 2012;265(3):819–831.Available from: http://www.ncbi.nlm.nih.gov/pubmed/23175545

Rockey D, Caldwell AH, Goodman ZD, Nelson RC, Smith AD. AASLD Position Paper: Liver Biopsy. HEPATOLOGY 2009; 49:1017–1044

Grant A, Neuberger J. Guidelines on the use of liver biopsy in clinical practice. British Society of Gastroenterology. Gut 1999;45(Suppl 4): IV1-IV11.Available from:http://www.ncbi.nlm.nih.gov/pubmed/10485854

Eisenberg E, Konopniki M, Veitsman E, Kramskay R, Gaitini D, Baruch Y. Prevalence and characteristics of pain induced by percutaneous liver biopsy. AnesthAnalg 2003;96(5):1392–1396.Available from:http://www.ncbi.nlm.nih.gov/pubmed/12707140

QianLX , Wang B. Analysis of the complications of liver biopsies using three different methods. ZhonghuaGanZang Bing ZaZhi 2007;15:47-9

Caldwell SH. Controlling pain in liver biopsy, or “we will probably need to repeat the biopsy in a year or two to assess the response”. Am J Gastroenterol 2001; 96: 1327–1329

Tan KT, Rajan DK, Kachura JR, Hayeems E, Simons ME, Ho CS. Pain after percutaneous liver biopsy for diffuse hepatic disease: a randomized trial comparing subcostal and intercostal approaches. J Vas Interv Radiol.2005;16(9):1215-19

Norman Oneil Machado (2011). Complications of Liver Biopsy - Risk Factors, Management and Recommendations, Liver Biopsy, DrHirokazu Takahashi (Ed.), ISBN: 978-953-307-644-7, InTech, DOI: 10.5772/21979. Available from: http://www.intechopen.com/books/liver-biopsy/complications-of-liver-biopsy-risk-factors-management-and-recommendations

Cadranel JF, Rufat P, Degos F. Practices of liver biopsy in France: results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the Study of the Liver (AFEF). Hepatology 2000;32(3):477–481.

Lindor KD, Bru C, Jorgensen RA , Rakela J, Bordas JM, Gross JB et al. The role of ultrasonography and automatic needle biopsy in outpatient percutaneous liver biopsy. Hepatology.1996;23(5):1079-83. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8621137

Riley TR 3rd. Predictors of pain medication use after percutaneous liver biopsy. Dig Dis Sci.2002;47(10):2151-53


  • There are currently no refbacks.

© Copyright PJR 2008-